Shared system for storing and exchanging immune-genetics (HLA and KIR) data
Integrated Exchange and Storage of Current- and Future-Generation Immunogenomic Data
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11327264
This project builds easy-to-use tools to collect, store, and share human immune-genetics information like HLA and KIR so patients needing transplants or those with autoimmune, infectious, or cancer conditions can benefit from better matching and research.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11327264 on ClinicalTrials.gov |
What this research studies
From my perspective, the team is creating standardized tools and databases that handle the complex, highly variable genes that control immune responses (HLA and KIR). They are combining existing formats and new standards so clinics and labs can upload, exchange, and analyze immunogenomic data reliably. The effort focuses on making these tools clinical-grade so they can support donor matching for bone marrow and organ transplants and help research into autoimmune, infectious, and cancer conditions. By supporting current and future sequencing technologies, the system aims to keep patient data interoperable and useful across hospitals and research centers.
Who could benefit from this research
Good fit: Ideal participants are people needing bone marrow or organ transplants, patients with autoimmune, infectious, or immune-related cancers, or individuals willing to share their HLA/KIR genetic data for research.
Not a fit: People whose health issues are unrelated to immune genetics or who do not want to share genetic information are unlikely to see direct benefits from this project.
Why it matters
Potential benefit: If successful, this could make donor matching more accurate and speed up research that leads to better diagnoses and personalized immune-based treatments.
How similar studies have performed: This work builds on previously developed and widely adopted immunogenomic standards and tools, so it extends proven approaches rather than starting from scratch.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MACK, STEVEN JOHN — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: MACK, STEVEN JOHN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.